

Medium-Cut-off (MCO) Membranes Reduce Inflammation In Chronic Dialysis Patients: a randomized, controlled "First in Man"-Trial

D.Zickler¹, R. Schindler¹, P. Martus⁶, M. Pawlak⁴, K. Willy¹, M. Storr³, M. Hulko³, T. Boehler³, M. Templin⁴, B. Trojanowicz², C. Ulrich², M. Glomb⁵, K. Liehr⁵, C.Henning⁵, K.Werner³, R. Fiedler², M. Girndt²

¹Charité-Virchow Clinic, Department of Nephrology and Internal Intensive Care Medicine, Berlin, Germany, daniel.zickler@charite.de; ²Department of Internal Medicine II, Martin-Luther-University Halle, Germany; ³Department of Research and Development, Gambro Dialysatoren GmbH, Hechingen, Germany; ⁴NMI TechnologyTransfer GmbH, Reutlingen, Germany, ⁵Institute for Food Chemistry, Martin-Luther-University Halle, Germany; ⁵ Institute for Clinical Epidemiology and Internal Intensive Care Medicine, Berlin, Germany, daniel.zickler@charite.de; ²Department of Internal Medicine, II, Martin-Luther-University Halle, Germany; ⁴NMI TechnologyTransfer GmbH, Reutlingen, Germany, ⁵Institute for Food Chemistry, University of Tübingen, Germany

Background

Mortality in dialysis patients might be related to reduced clearance of pro-inflammatory mediators. A new MCO membrane with better permeability for molecules up to 45 kDa was tested clinically for the first time.

Methods:

The randomized crossover trial in 48 patients compared MCO to High-flux (HF) dialysis of 4 weeks duration each plus 8 weeks extension phase.

Primary endpoint was the gene expression of TNFa and IL-6 in peripheral whole blood, secondary endpoints were plasma levels of specified inflammatory mediators and cytokines.

Results:

The primary end point TNF-alpha- and IL6 mRNA in leucocytes was reduced to a greater extent with MCO.

A significant difference between MCO and HF after 4 weeks was observed for sTNF-R1, kappa and lambda free light chains, albumin, urea and Lp-PLA2 (table 1).


After à significant drop after four weeks of MCO dialysis, albumin concentrations stabilized after 12 weeks (table 2).

Conclusions:


MCO membranes modulate inflammation in dialysis patients.


Enhanced removal of soluble mediators influences the transcription of pro-inflammatory cytokines in peripheral leukocytes.

These results encourage further investigations with longer treatment periods and clinically relevant endpoints.



	High-flux		MCO		
	Start	End	Start	End	
Albumin g/l	37.6 ± 2.3	37.9 ± 3.5	35.7 ± 4.5	36.4 ± 3.9	
CRP mg/l	5.7 ± 6.5	7.2 ± 8.5	12.6 ± 18.8	16.9 ± 48.4	
TNF- α mRNA	1.06 ± 0.67	1.03 ± 0.43	0.80 ± 0.25	0.87 ± 0.31	
IL-6 mRNA	1.00 ± 0.85	0.89 ± 0.73	0.53 ± 0.29	0.62 ± 0.42	








Table 1: Long-term plasma levels before and after 4 weeks treatment with High-flux / MCO. Shown are only parameters with a significant change after the MCO-period. *=p<0.05 vs. T=0; **=p<0.01 vs. T=0

	High-flux		мсо		p MCO vs HF
	T=0	T= 4 weeks	T=0	T= 4 weeks	
Clinical parameters					
Albumin g/l	36.6 ± 3.2	37.5 ± 2.7	37.0 ± 3.6	35.3 ± 3.7**	< 0.001
CRP mg/l	13.4 ± 25.5	9.6 ± 15.7	15.3 ± 30.0	9.3 ± 14.5	n.s.
Beta2M mg/l	27.0 ± 9.1	26.1 ± 8.6	26.9 ± 8.4	25.7 ± 8.1**	n.s.
TNF-/TNFR-Family					
sTNF-R1 ng/ml	13.3 ± 4.7	12.9 ± 4.7	13.0 ± 4.4	11.0 ± 3.7**	0.01
TNF-α pg/ml	23.4 ± 7.3	22.2 ± 6.0	24.1 ± 8.1	20.6 ± 5.8**	n.s.
Main cytokines					
IFN-γ pg/ml	16.0 ± 19.7	14.4 ± 17.8	17.5 ± 19	11.8 ± 12**	n.s.
IL-10 pg/ml	59 ± 355	47 ± 280	51 ± 287	65 ± 402**	n.s.
IL-6 pg/ml	9.8 ± 20.5	5.5± 4.5*	9.0 ± 13.2	6.0 ± 5.9**	n.s.
Other					
FLC kappa mg/l	134 ± 65	140 ± 77	137 ± 65	120 ± 54**	0.003
FLC lambda mg/l	91 ± 42	91 ± 44	95 ± 46	79 ± 36**	< 0.001
Lp-PLA2 ng/ml	180 ± 90	185 ± 108	156 ± 76	189 ± 101**	0.026







